IceCure Medical (NASDAQ:ICCM) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a report released on Wednesday morning,Benzinga reports. HC Wainwright currently has a $2.50 target price on the stock.

Separately, Alliance Global Partners upgraded IceCure Medical to a “strong-buy” rating in a research report on Friday, November 1st.

IceCure Medical Price Performance

Shares of NASDAQ:ICCM opened at $0.83 on Wednesday. The firm has a market capitalization of $37.96 million, a PE ratio of -2.87 and a beta of 0.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.54 and a current ratio of 2.67. IceCure Medical has a 52-week low of $0.48 and a 52-week high of $1.57. The firm has a fifty day moving average of $0.65 and a 200 day moving average of $0.72.

Institutional Investors Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC acquired a new stake in IceCure Medical Ltd (NASDAQ:ICCM) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.